Highlights from ASH 2023: A Canadian Perspective on CLL

In this episode, Dr. David Macdonald and Dr. Versha Banerji discuss the key presentations on CLL presented at ASH 2023. 

30 minutes

Live from ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM

In episode, Dr. Rami Kotb and Dr Donna Reece discuss results of the CMRG Isa-CYBORD trial and their implications for Canadian clinical practice.

20 minutes

Video Capsule Series - First Line la/mUC Evolving Treatment Strategies: S2 Ep1 - Unmet Needs

This episode with Dr. Normand Blais discusses the unmet treatment needs for la/mUC in the 1L setting in Canada.  

11 minutes

Video Capsule Series - First Line la/mUC Evolving Treatment Strategies: S2 Ep2 - 1L Treatment

This episode with Dr. Terence Friedlander discusses the 1L treatment of la/mUC

15 minutes

Video Capsule Series - First Line la/mUC Evolving Treatment Strategies: S2 Ep3 - Case Discussion

This episode with Dr. Srikala Sridhar presents a clinical case on the treatment of la/mUC.  

8 minutes

Video Capsule Series - First Line la/mUC Evolving Treatment Strategies: S2 Ep4 - Round Table Discussion

In this fourth episode, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective in a round table discussion.  

27 minutes

Video Capsule Series - First Line la/mUC Evolving Treatment Strategies: S2 Ep5 - ESMO 2023: Discussion on 1L LA/mUC

In this fifth episode, Dr. Thomas Powles, Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl discuss the impact of data on 1L la/mUC presented at ESMO 2023.  

34 minutes

Monoclonal Antibodies as COVID-19 Prophylaxis in Immunocompromised Patients 

We discuss the use of MAbs as COVID-19 prophylaxis for people with immunocompromised conditions with Dr. Juthaporn Cowan.  

24 minutes

Management of BTKi Associated Adverse Events: A Pharmacist's Perspective 

We discuss the management of BTKi associated AEs for the treatment of hematological malignancies with pharmacist, Dominic Duquette. 

54 minutes

Prise en charge des cancers indolents touchant les lymphocytes B, traités par des BTKis

Programme de formation à l’intention des pharmaciens avec Dominic Duquette.    

103 minutes

Management of BTKi Associated Adverse Events: A Nurse's Perspective 

We discuss the management of BTKi associated AEs for the treatment of hematological malignancies with nurse practitioner, Shannon Nixon. 

28 minutes

Video Capsule Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - S1 E1: Introduction to EV

We discuss the clinical data on enfortumab vedotin for the treatment of patients with la/mUC with Dr. Normand Blais and Dr. Joel Claveau. 

17 minutes

Video Capsule Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - S1 E2: Skin Reactions

We discuss the management of skin reactions with enfortumab vedotin for the treatment of patients with la/mUC with Dr. Normand Blais and Dr. Joel Claveau. 

32 minutes

Video Capsule Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - S1 E3: Peripheral Neuropathy

We discuss the management of peripheral neuropathy with enfortumab vedotin for the treatment of patients with la/mUC with Dr. Srikala Sridhar and Dr. Warren Mason

23 minutes

Video Capsule Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - S1 E4: Hyperglycemia

We discuss the management of hyperglycemia with enfortumab vedotin for the treatment of patients with la/mUC with Dr. Nimira Alimohamed and Dr. Minna Woo. 

31 minutes

Transcript_Panel Discussion. CCOLD.pdf

Live from CCOLD: Treatment of CLL

Live from the CCOLD meeting in Banff, Alberta, we discuss the treatment of CLL with Dr. Laurie Sehn (BC Cancer), Dr. Matthew Davids, (Dana Farber) and Dr. Constantine Tam (University of Melbourne). 

Transcript available. 

31 minutes

Evolving Therapeutic Approach in Advanced Biliary Tract Cancer

Dr. Howard Lim discusses the evolving therapeutic approach for the treatment of BTC. 

9 minutes

Évolution des traitements du cancer des voies biliaires avancé inopérable

Dr. Kim Ma discusses the evolving therapeutic approach for the treatment of BTC. (French)

10 minutes

Treatment of COVID-19 with Evusheld: A Canadian Perspective on the TACKLE Trial

Dr. Zain Chagla presents a summary of the TACKLE trial and a Canadian perspective on Evusheld for the treatment of COVID-19.

17 minutes

Urothelial Carcinoma: EV-301 Update from ASCO 2022

Dr. Nimira Alimohamed discusses updates on the treatment of urothelial carcinoma, focusing on data from the EV-301 trial presented at the ASCO 2022 virtual meeting. 

9 minutes

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022 (French)

Dr. Jean-Francois Larouche discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting. (In French)


10 minutes

Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022

Dr. John Kuruvilla discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting. 

18 minutes

Highlights from ASCO/EHA 2021: Updates in CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASCO/EHA 2021 virtual meetings. 

24 minutes

ASCO/EHA 2021: traitement de la LLC

Le Dr Stephane Doucet discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASCO et EHA de 2021.  

40 minutes

Highlights from ASH 2021: Updates in CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2021 meeting. 

22 minutes

ASH 2021: traitement de la LLC

Dr. Michel Pavic, Onco-hématologue a l’Estrie-CHUS, discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2021.   


27 minutes

CGP Report: Recommendations for Funders

Dr. Sandeep Sehdev discusses recommendations for funding comprehensive genomic profiling for payers in Canada. The full CGP report is available at: https://www.impactmedicom.com/publications/reports. Funding for the CGP report was provided by AstraZeneca, Roche, and Illumina. 

35 minutes

ASH 2020: Updates on CLL

Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2020 virtual meeting. 

18 minutes

ASH 2020: traitement de la LLC 

La Dre Silvy Lachance discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2020.


36 minutes

BTK Inhibitors for the Frontline Treatment of CLL 

Dr. Laurie Sehn discusses the management of BTK-related toxicities, based on a recently published paper in Current Oncology by Dr. Laurie Sehn, Dr. Andrew Aw & Dr. Sue Robinson. 

28 minutes

Les inhibiteurs de la BTK pour le traitement de première intention de la LLC Présentation

La Dre Inès Chamakhi discute de la prise en charge des toxicités liées aux inhibiteurs de la BTK d’après un article récemment publié dans la revue Current Oncology par la Dre Laurie Sehn , le Dr Andrew Aw et la Dre Sue Robinson. 

20 minutes

Treatment of CLL during COVID-19

Dr. Laurie Sehn discusses the treatment of CLL during the coronavirus pandemic, based on a recently published paper by Dr. Laurie Sehn, Dr. Philip Kuruvilla, and Dr. Julie Stakiw. The full paper can be found here: https://www.current-oncology.com/inde...


20 minutes

Prise en charge de la LLC au Canada pendant la pandémie de COVID-19

Dr Michel Pavic discute du traitement de la LLC à l’ère de la pandémie de Covid 19, d’après les résultats d’un article publié récemment dans la revue Current Oncology (Dre Laurie Sehn, Dr Philip Kuruvilla et Dre Julie Stakiw). 

20 minutes

ASCO 2020: CLL Updates

Dr. Mona Shafey presents key updates on the treatment of chronic lymphocytic leukemia from the ASCO 2020 virtual Meeting.

32 minutes

ENGLISH: NGS Guidelines

Dr. Stephen Yip, Director of the Cancer Genetics & Genomics Lab at BC Cancer in Vancouver, British Columbia, presents a summary of the first Canadian guidelines on Next Generation Sequencing (NGS). The published guidelines can be found in the April issue of Current Oncology. 

2 hours

FRENCH: NGS Guidelines

Dr. Patrice Desmeules, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec, QC presents a summary of the recently published Canadian guidelines on next generation sequencing (NGS). 

1 hr 40 minutes

ASH 2019: CLL Updates

Dr. Versha Banerji Discusses Practice-Changing Studies in Treatment-Naive CLL.

23 minutes

**Funding provided by BeiGene ULC, Sanofi-Aventis Canada, Seagen Canada, AstraZeneca, Merck

💬 416-434-8923